Foreign Filer Report • Nov 3, 2021
Foreign Filer Report
Open in ViewerOpens in native device viewer
Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result� false
| ����� ��"� | 2 380 |
| EVOGENE LTD | |
| Corporation no: 512838723 | 10571 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 03/11/2021 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2021-02-162729 | Time of broadcast: 12:42 12:42 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onLavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result�
Lavie_result_launch_Eng_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 19/10/2021 |
| Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121 , Tel: 08-9311900 , Fax: 08-9466724 | |
| E-mail address: [email protected] Company site: www.evogene.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Masliah Sassi Position of Signatory in the reporting corporation: Director of Legal Affairs & Company Secretary Name of Employer Company: | |
| Address: Gad Feinstein 13 , Rehovot 7612001 Telephone: 08-9311901 Facsimile: 08-9466724 E-mail: [email protected] 1 | |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.